Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcript… Read more
Market Cap & Net Worth: Anbio Biotechnology Class A Ordinary Shares (NNNN)
Anbio Biotechnology Class A Ordinary Shares (NASDAQ:NNNN) has a market capitalization of $943.66 Million ($943.66 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7951 globally and #4109 in its home market, demonstrating a -3.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anbio Biotechnology Class A Ordinary Shares's stock price $21.50 by its total outstanding shares 43891200 (43.89 Million).
Anbio Biotechnology Class A Ordinary Shares Market Cap History: 2025 to 2026
Anbio Biotechnology Class A Ordinary Shares's market capitalization history from 2025 to 2026. Data shows growth from $1.32 Billion to $943.66 Million (0.00% CAGR).
Index Memberships
Anbio Biotechnology Class A Ordinary Shares is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.04% | #219 of 976 |
Weight: Anbio Biotechnology Class A Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Anbio Biotechnology Class A Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anbio Biotechnology Class A Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NNNN by Market Capitalization
Companies near Anbio Biotechnology Class A Ordinary Shares in the global market cap rankings as of March 19, 2026.
Key companies related to Anbio Biotechnology Class A Ordinary Shares by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #98 globally with a market cap of $170.40 Billion USD.
- EssilorLuxottica Société anonyme (PINK:ESLOF): Ranked #263 globally with a market cap of $78.22 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #362 globally with a market cap of $61.18 Billion USD ( €59.61 Billion EUR).
- Becton Dickinson and Company (NYSE:BDX): Ranked #472 globally with a market cap of $45.90 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #98 | Intuitive Surgical Inc | NASDAQ:ISRG | $170.40 Billion | $482.76 |
| #263 | EssilorLuxottica Société anonyme | PINK:ESLOF | $78.22 Billion | $265.00 |
| #362 | EssilorLuxottica S. A. | PA:EL | $61.18 Billion | €203.00 |
| #472 | Becton Dickinson and Company | NYSE:BDX | $45.90 Billion | $161.64 |
Anbio Biotechnology Class A Ordinary Shares Historical Marketcap From 2025 to 2026
Between 2025 and today, Anbio Biotechnology Class A Ordinary Shares's market cap moved from $1.32 Billion to $ 943.66 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $943.66 Million | -28.50% |
| 2025 | $1.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Anbio Biotechnology Class A Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $943.66 Million USD |
| MoneyControl | $943.66 Million USD |
| MarketWatch | $943.66 Million USD |
| marketcap.company | $943.66 Million USD |
| Reuters | $943.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.